Mathieu Puyade

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro et al. · Blood · 2016 · 276 citations · Full text

Medicine, Oncology, Hematologic Oncology +8

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Marion Allouchery, Thomas Lombard, M. Martin et al. · Journal for ImmunoTherapy of Cancer · 2020 · 129 citations · Full text

Medicine, Oncology, Pharmacology +17

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé et al. · Blood Advances · 2019 · 121 citations · Full text

Medicine, Hematology, Oncology +17

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

Lucie Obéric, Frédéric Peyrade, Mathieu Puyade et al. · Journal of Clinical Oncology · 2021 · 73 citations · Full text

Medicine, Oncology, Pharmacotherapy +17